Expanding Cancer Screening: The Future of Blood-Based Testing
Closing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.
Read More
Future of Multi-Cancer Early Detection: A Recap and Horizon
Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.
Read More
Moonshot Cancer Initiative and MCED Consortium: Advancing Cancer Detection
Explore the pivotal role of the Moonshot Cancer Initiative and MCED Consortium in shaping the landscape of early cancer detection and screening, with a focus on innovative screening tools and legislative support.
Read More
Future Needs and Challenges of Multi-Cancer Early Detection Tests
Implementation challenges and the importance of equitable access in the future of multi-cancer early detection tests.
Read More
Efficiency in Diagnostic Resolution: Imaging vs. Molecular Tissue of Origin
Shared insight into the efficiency of diagnostic resolution approaches, comparing imaging-based and molecular tissue of origin strategies in multi-cancer early detection testing.
Read More
Advancing Cancer Detection With the ASCEND Trial: Key Objectives and Rationale
Expert perspectives about the ASCEND trial, its study design, and the critical role it plays in developing advanced cancer detection methods.
Read More
Advancements in Multi-Biomarker Cancer Testing
Key opinion leaders review the rationale behind multi-biomarker approaches and how they're shaping the future of cancer detection and research.
Read More
Cancer Screening Breakthroughs: Implications for Clinical Practice
Discover the potential clinical implications of groundbreaking cancer screening studies, DETECT-A and PATHFINDER, and the evolving landscape of multi-cancer early detection.
Read More
Latest Insights from the PATHFINDER Study: Cancer Detection Advancements
Panelists explore recent findings of the PATHFINDER study, focusing on the objectives, study design, key results, and differences from previous studies, shedding light on the potential of early cancer detection tests.
Read More
DETECT-A Study: Advancements in Early Cancer Detection
Shared insight into findings of the DETECT-A study, a prospective interventional trial, covering feasibility, safety, and performance of multicancer early detection tests in a healthcare system setting.
Read More
Addressing Healthcare Inequity With Accessible Multicancer Early Detection
The potential of MCED testing to reduce health inequities and an examination of accessibility, including FDA approval, physician education, patient awareness, affordability, and logistical support.
Read More
The Transformative Potential of Multicancer Early Detection Testing
Expert panelists delve into multicancer early detection testing and discuss its potential to revolutionize cancer screening, close healthcare gaps, and complement standard care approaches.
Read More
Addressing Health Inequities in Cancer Screening: Challenges and Opportunities
September 29th 2023Explore critical issues surrounding health disparities in cancer screening, as discussed by experts, and the urgent need to bridge gaps in access, trust, and follow-up care for underserved populations.
Read More
Dr. Beer on the Immune-Related Adverse Events of Ipilimumab in mCRPC
May 16th 2014Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.
Read More
Dr. Beer on the Implications of the PREVAIL Study
February 3rd 2014Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.
Read More